{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:47:35Z","timestamp":1792716455580,"version":"4.5.0"},"reference-count":98,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Bleeding complications are a significant concern in the management of acute coronary syndromes (ACS). The evidence from clinical trials demonstrates the need for balancing efficacy in reducing ischemic events with safety concerns, as bleeding events adversely affect prognosis and mortality. Pharmacological agents like aspirin, P2Y12 inhibitors (e.g., prasugrel, ticagrelor), glycoprotein IIb\/IIIa inhibitors, and heparins are fundamental to ACS treatment but carry varying bleeding risks depending on individual patient profile. Recent advancements in risk stratification tools have enabled tailored approaches to dual antiplatelet therapy (DAPT), optimizing its duration based on bleeding and thrombotic risks. Further Emerging therapies, including shortened DAPT protocols and P2Y12 inhibitor monotherapy, have shown promise in minimizing bleeding while maintaining clinical efficacy. The findings underscore the importance of personalized antithrombotic regimens in ACS management, emphasizing precise risk assessment to enhance outcomes and mitigate adverse events. This review examines the mechanisms, risk factors, and strategies to mitigate bleeding associated with anticoagulant and antiplatelet therapies in ACS.<\/jats:p>","DOI":"10.3390\/jcm14103391","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T06:40:23Z","timestamp":1747118423000},"page":"3391","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bleeding Complications of Anticoagulation Therapy Used in the Treatment of Acute Coronary Syndromes\u2014Review of the Literature"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-463X","authenticated-orcid":false,"given":"Micha\u0142","family":"Kosowski","sequence":"first","affiliation":[{"name":"2nd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kocjan","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6112-4225","authenticated-orcid":false,"given":"Michalina","family":"Mazurkiewicz","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gamrot-Wrzo\u0142","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology and Oncological Laryngology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Ryl","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Care, Municipal Hospital in Zabrze-Biskupice, 41-803 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1453-5164","authenticated-orcid":false,"given":"Krzysztof","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Department of Urology and Urological Oncology in Rybnik, Faculty of Medical Sciences in Zabrze, Academy of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Kawecki","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-8159","authenticated-orcid":false,"given":"Tomasz","family":"Kukulski","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Kawecki","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Morawiec-Migas","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2016.02.056","article-title":"Validation of BARC bleeding criteria in patients with acute coronary syndromes: The TRACER trial","volume":"67","author":"Vranckx","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point","volume":"51","author":"Ndrepepa","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00062-020-00910-5","article-title":"Antiplatelet Drugs for Neurointerventions: Part 1 Clinical Pharmacology","volume":"30","author":"Pearce","year":"2020","journal-title":"Clin. Neuroradiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pelliccia, F., Gragnano, F., Pasceri, V., Cesaro, A., Zimarino, M., and Calabr\u00f2, P. (2022). Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133574"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials","volume":"11","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e008708","DOI":"10.1161\/JAHA.118.008708","article-title":"CREDO-Kyoto PCI\/CABG Registry Cohort 2, RESET, and NEXT trial investigators. Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores","volume":"7","author":"Natsuaki","year":"2018","journal-title":"J. Am. Heart. Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2459\/JCM.0000000000000362","article-title":"BleeMACS: Rationale and design of the study","volume":"17","author":"Henriques","year":"2016","journal-title":"J. Cardiovasc. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1076029619853638","DOI":"10.1177\/1076029619853638","article-title":"Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention","volume":"25","author":"Zhao","year":"2019","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Garc\u00eda Rodr\u00edguez, L.A., Mart\u00edn-P\u00e9rez, M., Hennekens, C.H., Rothwell, P.M., and Lanas, A. (2016). Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160046"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The efficacy of Xience\/Promus versus Cypher to reduce late loss after stenting (excellent) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2017.11.009","article-title":"Effect of procedure and coronary lesion characteristics on clinical outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: Insights from the PIONEER AF-PCI trial","volume":"11","author":"Kerneis","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Eng. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Eng. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5603\/cj.96076","article-title":"CangrelorExpanding therapeutic options in patients with acute coronary syndrome","volume":"31","author":"Kubica","year":"2024","journal-title":"Cardiol. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N. Eng. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N. Eng. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Eng. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.100.20.2045","article-title":"Platelet glycoprotein IIb\/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention","volume":"100","author":"Boersma","year":"1999","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/VHRM.S4168","article-title":"Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention","volume":"6","author":"Tricoci","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/eurheartj\/16.suppl_L.43","article-title":"An overview of the results of the EPIC trial","volume":"16","author":"Califf","year":"1995","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"EPILOG Investigators (1997). Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Eng. J. Med., 336, 1689\u20131696.","DOI":"10.1056\/NEJM199706123362401"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"EPISTENT Investigators (1998). Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade. The EPISTENT investigators. Evaluation of platelet IIb\/IIIa inhibitor for stenting. Lancet, 352, 87\u201392.","DOI":"10.1016\/S0140-6736(98)06113-3"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Capture Investigators (1997). Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet, 349, 1429\u20131435.","DOI":"10.1016\/S0140-6736(96)10452-9"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"The PURSUIT Investigators (1999). Stroke in patients with acute coronary syndromes. Incidence and outcomes in platelet glycoprotein IIb\/IIIa in unstable angina: Receptor suppresion using integrilin therapy (PURSUIT) Trial. Circulation, 99, 2371\u20132377.","DOI":"10.1161\/01.CIR.99.18.2371"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"(1998). The PRISM Study Investigators: A comparison of aspirin plus tyrofibane with aspirin plus heparin for unstable angina. N. Eng. J. Med., 338, 1498\u20131505.","DOI":"10.1056\/NEJM199805213382103"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"The ESPRIT Investigators (2000). Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet, 356, 2037\u20132044.","DOI":"10.1016\/S0140-6736(00)03400-0"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"IMPACT-II Investigators (1997). Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet, 349, 1422\u20131428.","DOI":"10.1016\/S0140-6736(96)10172-0"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N. Eng. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: The RESET trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Eng. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: The TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: A systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Eng. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcin.2021.07.016","article-title":"3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation","volume":"14","author":"Mehran","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: One-Month DAPT Trial","volume":"14","author":"Hong","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40265-024-02034-3","article-title":"Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis","volume":"84","author":"Agbaedeng","year":"2024","journal-title":"Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"33B","DOI":"10.1016\/S0735-1097(86)80005-5","article-title":"Pharmacology of thrombolytic drugs","volume":"8","author":"Verstraete","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MBC.0000000000001231","article-title":"Fibrinolytic drugs induced hemorrhage: Mechanisms and solutions","volume":"34","author":"Tang","year":"2023","journal-title":"Blood Coagul. Fibrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-981-13-7709-9_15","article-title":"Fibrinolytic Enzymes for Thrombolytic Therapy","volume":"1148","author":"Kumar","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1538-7836.2009.03701.x","article-title":"Direct fibrinolytic agents: Biochemical attributes, preclinical foundation and clinical potential","volume":"8","author":"Marder","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijbiomac.2019.11.157","article-title":"Preparation of PEG-grafted chitosan\/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme","volume":"143","author":"Baharifar","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.actbio.2018.01.038","article-title":"Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis","volume":"70","author":"Zhang","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1021\/acs.bioconjchem.7b00770","article-title":"Conjugation with eight-arm PEG markedly improves the in vitro activity and prolongs the blood circulation of staphylokinase","volume":"29","author":"Qi","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1172\/JCI112546","article-title":"Localization of the binding site of tissue-type plasminogen activator to fibrin","volume":"78","author":"Ichinose","year":"1986","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2107727","article-title":"A randomized trial of intravenous alteplase before endovascular treatment for stroke","volume":"385","author":"LeCouffe","year":"2021","journal-title":"N. Eng. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/bjh.17942","article-title":"Enhanced clot lysis by a single point mutation in a reteplase variant","volume":"196","author":"Chen","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1161\/STROKEAHA.120.029749","article-title":"Tenecteplase thrombolysis for acute ischemic stroke","volume":"51","author":"Warach","year":"2020","journal-title":"Stroke"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/WNL.42.5.976","article-title":"Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke","volume":"42","author":"Mori","year":"1992","journal-title":"Neurology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/cns.13093","article-title":"Batroxobin in combination with anticoagulation may promote venous sinus recanalization in cerebral venous thrombosis: A real-world experience","volume":"25","author":"Ding","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0049-3848(75)90025-0","article-title":"The effect of defibrase on arterial thrombus formation","volume":"6","author":"Bourgain","year":"1975","journal-title":"Thromb. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0049-3848(97)00066-2","article-title":"Further characterization and thrombolytic activity in a rat model of a fibrinogenase from vipera lebetina venom","volume":"86","author":"Gasmi","year":"1997","journal-title":"Thromb. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1084\/jem.58.4.485","article-title":"The Fibrinolytic Activity of Hemolytic Streptococci","volume":"58","author":"Tillett","year":"1933","journal-title":"J. Exp. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1084\/jem.95.5.449","article-title":"The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase)","volume":"95","author":"Johnson","year":"1952","journal-title":"J. Exp. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1172\/JCI102973","article-title":"The fibrinolytic activity of streptokinase activated human plasmin","volume":"33","author":"Sherry","year":"1954","journal-title":"J. Clin. Investing"},{"key":"ref_64","first-page":"287","article-title":"The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy","volume":"71","author":"Fletcher","year":"1958","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/01.CIR.19.1.7","article-title":"Fibrinolytic (plasmin) therapy of experimental coronary thrombi with alteration of the evolution of myocardial infarction","volume":"19","author":"Ruegsegger","year":"1959","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico (1990). GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet, 336, 65.","DOI":"10.1016\/0140-6736(90)91589-3"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","article-title":"Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction","volume":"368","author":"Armstrong","year":"2013","journal-title":"N. Eng. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s13054-016-1530-z","article-title":"Prehospital fibrinolysis versus primary percutaneous coronary intervention in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Roule","year":"2016","journal-title":"Crit. Care"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","article-title":"Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Jauch","year":"2013","journal-title":"Stroke"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/01616412.2019.1580454","article-title":"Low-dose rt-PA may not decrease the incidence of symptomatic intracranial haemorrhage in patients with high risk of symptomatic intracranial haemorrhage","volume":"41","author":"Liu","year":"2019","journal-title":"Neurol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of Heparin and Related Drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_74","unstructured":"Warnock, L.B., and Huang, D. (2023). Heparin, StatPearls Publishing."},{"key":"ref_75","unstructured":"Solari, F., and Varacallo, M. (2025). Low-Molecular-Weight Heparin (LMWH). StatPearls, StatPearls Publishing."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin","volume":"21","author":"Hirsh","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"ref_77","first-page":"137","article-title":"Development of a Synthetic Heparin Pentasaccharide: Fondaparinux","volume":"19","author":"Walenga","year":"2002","journal-title":"Turk. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e012184","DOI":"10.1161\/JAHA.119.012184","article-title":"Fondaparinux Sodium Compared with Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis","volume":"8","author":"Kumar","year":"2019","journal-title":"J. Am. Heart. Assoc."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.carrev.2024.03.025","article-title":"Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-Outcomes at two years","volume":"26","author":"Omerovic","year":"2024","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1161\/CIRCULATIONAHA.123.067079","article-title":"RIGHT Investigators. Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial","volume":"149","author":"Yan","year":"2024","journal-title":"Circulation"},{"key":"ref_81","first-page":"AT10782","article-title":"The Effects of Bivalirudin and Ordinary Heparin on the Incidence of Bleeding Events and the Level of Inflammation after Interventional Therapy for Acute Myocardial Infarction","volume":"24","author":"Wu","year":"2024","journal-title":"Altern. Ther. Health Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.amjcard.2024.02.033","article-title":"Safety and Efficacy of Enoxaparin During Low-Risk Elective Percutaneous Coronary Intervention","volume":"218","author":"Alturkmani","year":"2024","journal-title":"Am. J. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Kumar, P., Shaik, M., and Yuan, J. (2017). Choosing between enoxaparin and fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis. BMC Cardiovasc. Disord., 17.","DOI":"10.1186\/s12872-017-0552-z"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000441442","article-title":"Comparison between fondaparinux and low-molecular-weight heparin in patients with acute coronary syndrome: A meta-analysis","volume":"133","author":"Qiao","year":"2016","journal-title":"Cardiology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2022.04.023","article-title":"Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations","volume":"101","author":"Imberti","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ebiom.2017.05.010","article-title":"CRUSADE Score is Superior to Platelet Function Testing for Prediction of Bleeding in Patients Following Coronary Interventions","volume":"21","author":"Bang","year":"2017","journal-title":"eBioMedicine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/europace\/euac020","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society","volume":"24","author":"Gorog","year":"2022","journal-title":"Europace"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"euad226","DOI":"10.1093\/europace\/euad226","article-title":"Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal","volume":"25","author":"Lip","year":"2023","journal-title":"Europace"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2","DOI":"10.31083\/j.rcm2301002","article-title":"Bleeding risk in patients with atrial fibrillation treated with combined anti-platelet and non-vitamin K antagonist oral anticoagulant therapy","volume":"23","author":"Shin","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_90","first-page":"536","article-title":"Impact of vascular access on outcome after PCI in patients at high bleeding risk: A pre-specified sub-analysis of the LEADERS FREE trial","volume":"73","author":"Hovasse","year":"2020","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40119-023-00343-4","article-title":"Impact of Access Site on Periprocedural Bleeding and Cerebral and Coronary Events in High-Bleeding-Risk Percutaneous Coronary Intervention: Findings from the RIVA-PCI Trial","volume":"13","author":"Borlich","year":"2024","journal-title":"Cardiol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2018-06-820746","article-title":"Treatment of bleeding complications in patients on anticoagulant therapy","volume":"133","author":"Piran","year":"2019","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N. Eng. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.amjmed.2016.03.042","article-title":"Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial","volume":"129","author":"Vaduganathan","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/MEG.0000000000001125","article-title":"Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: A systematic review and meta-analysis","volume":"30","author":"Khan","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.carrev.2019.02.002","article-title":"Meta-analysis of efficacy and safety of proton pump inhibitors with dual antiplatelet therapy for coronary artery disease","volume":"20","author":"Khan","year":"2019","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/eurheartj\/ehz104","article-title":"Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction","volume":"40","author":"Sehested","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_98","first-page":"10","article-title":"Impact of In-Hospital Bleeding on Post-Discharge Therapies and Prognosis in Acute Coronary Syndromes","volume":"13","author":"Spadafora","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3391\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:31:41Z","timestamp":1760031101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":98,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14103391"],"URL":"https:\/\/doi.org\/10.3390\/jcm14103391","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}